Background and purpose: Depression is common in early phases of Alzheimer’s disease (AD) and may represent prodromal symptoms of dementia. Recent reports suggest that early memory deficits and neuropsychiatric symptoms are caused by soluble rather than aggregated bamyloid (Ab). Thus, we investigated the effects of soluble Ab1-42 on working memory and depressive/anxiety-related behaviour in rats and on 5-hydroxytryptaminergic neurotransmission and neurotrophin content in various brain regions. Experimental approach: Behavioural reactivity to novel object recognition, open field, elevated plus maze and forced swimming test were assessed 7 days after i.c.v. injection of Ab1-42 or its vehicle. BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) mRNA and protein levels and 5-hydroxytriptamine (5-HT) content were measured in the prefrontal cortex (PFC), striatum (STR) and nucleus accumbens (NAc). Key results: Ab1-42 did not affect the ability to distinguish between familiar and novel objects, but Ab-treated rats exhibited an increase in forced swimming immobility. No differences were revealed between experimental groups in the elevated plus maze test or in self-grooming (evaluated in the open field). In the PFC, but not STR or NAc, Ab-injected rats exhibited a selective reduction in 5-HT content, BDNF and NGF expression. Conclusions and implications: Our data suggest that soluble Ab-treated rats have a depressive, but not anxiogenic-like, profile, accompanied by brain region-dependent alterations in the expression of neurotrophins and 5-hydroxytryptaminergic neurotransmission. Hence, these alterations induced by soluble Ab might be sensitive indicators of early phases of AD and possible risk factors for the expression of neuropsychiatric symptoms in AD.

Soluble betaamyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?

GOVONI, STEFANO;
2010-01-01

Abstract

Background and purpose: Depression is common in early phases of Alzheimer’s disease (AD) and may represent prodromal symptoms of dementia. Recent reports suggest that early memory deficits and neuropsychiatric symptoms are caused by soluble rather than aggregated bamyloid (Ab). Thus, we investigated the effects of soluble Ab1-42 on working memory and depressive/anxiety-related behaviour in rats and on 5-hydroxytryptaminergic neurotransmission and neurotrophin content in various brain regions. Experimental approach: Behavioural reactivity to novel object recognition, open field, elevated plus maze and forced swimming test were assessed 7 days after i.c.v. injection of Ab1-42 or its vehicle. BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) mRNA and protein levels and 5-hydroxytriptamine (5-HT) content were measured in the prefrontal cortex (PFC), striatum (STR) and nucleus accumbens (NAc). Key results: Ab1-42 did not affect the ability to distinguish between familiar and novel objects, but Ab-treated rats exhibited an increase in forced swimming immobility. No differences were revealed between experimental groups in the elevated plus maze test or in self-grooming (evaluated in the open field). In the PFC, but not STR or NAc, Ab-injected rats exhibited a selective reduction in 5-HT content, BDNF and NGF expression. Conclusions and implications: Our data suggest that soluble Ab-treated rats have a depressive, but not anxiogenic-like, profile, accompanied by brain region-dependent alterations in the expression of neurotrophins and 5-hydroxytryptaminergic neurotransmission. Hence, these alterations induced by soluble Ab might be sensitive indicators of early phases of AD and possible risk factors for the expression of neuropsychiatric symptoms in AD.
2010
Pharmacology & Toxicology includes all aspects of pharmacology, toxicology, and pharmaceutics. Of particular importance are cellular and molecular pharmacology, drug design and metabolism, mechanisms of drug action, drug delivery, natural products, xenobiotics, and clinical therapeutics. Toxicology coverage considers cellular and molecular effects of harmful substances, environmental toxicology, occupational exposure, and clinical toxicology. Drug bulletins, drug updates, and pharmaceutical newsletters are excluded as are resources on pharmaceutical engineering. Medicinal chemistry, or synthesis and chemical analysis of pharmaceuticals are placed in the Chemistry & Analysis category.
Sì, ma tipo non specificato
Inglese
Internazionale
ELETTRONICO
159
8
1704
1715
Depression; Alzheimer's disease; Soluble betaamyloid
8
info:eu-repo/semantics/article
262
Colaianna, M; Tucci, P; Zotti, M; Morgese, Mg; Schiavone, S; Govoni, Stefano; Cuomo, V; Trabace, L.
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/208588
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact